If I really believed that was the Todos forecast, I would start unloading my shares. A hiccup in testing revenue from last quarter doesn't equate to Todos being on the verge of collapse. There are many parts in motion here. Focusing solely on the temporary Provista payroll issue is losing focus on the larger picture. Tollovid sales are still generating revenues. Tollovir EUAs are in the works and we may see movement on that in the near future. The vending initiative is supposed to be generating significant revenue soon, but we'll have to verify that in the filings.
If the 3CL Pharma fundraising doesn't meet expectations, I might start having concerns. Your mileage may vary.